1,720,977 research outputs found

    MSJ768433_supplementary_material – Supplemental material for Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis

    No full text
    Supplemental material, MSJ768433_supplementary_material for Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis by Johannes Lorscheider, Pascal Benkert, Carmen Lienert, Peter Hänni, Tobias Derfuss, Jens Kuhle, Ludwig Kappos and Özgür Yaldizli in Multiple Sclerosis Journal</p

    sj-tiff-1-msj-10.1177_13524585211047977 – Supplemental material for Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis

    No full text
    Supplemental material, sj-tiff-1-msj-10.1177_13524585211047977 for Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis by Tomas Uher, Eva Kubala Havrdova, Pascal Benkert, Niels Bergsland, Jan Krasensky, Barbora Srpova, Michael Dwyer, Michaela Tyblova, Stephanie Meier, Manuela Vaneckova, Dana Horakova, Robert Zivadinov, David Leppert, Tomas Kalincik and Jens Kuhle in Multiple Sclerosis Journal</p

    sj-docx-3-msj-10.1177_13524585211047977 – Supplemental material for Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis

    No full text
    Supplemental material, sj-docx-3-msj-10.1177_13524585211047977 for Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis by Tomas Uher, Eva Kubala Havrdova, Pascal Benkert, Niels Bergsland, Jan Krasensky, Barbora Srpova, Michael Dwyer, Michaela Tyblova, Stephanie Meier, Manuela Vaneckova, Dana Horakova, Robert Zivadinov, David Leppert, Tomas Kalincik and Jens Kuhle in Multiple Sclerosis Journal</p

    sj-docx-1-msj-10.1177_13524585211047977 – Supplemental material for Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis

    No full text
    Supplemental material, sj-docx-1-msj-10.1177_13524585211047977 for Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis by Tomas Uher, Eva Kubala Havrdova, Pascal Benkert, Niels Bergsland, Jan Krasensky, Barbora Srpova, Michael Dwyer, Michaela Tyblova, Stephanie Meier, Manuela Vaneckova, Dana Horakova, Robert Zivadinov, David Leppert, Tomas Kalincik and Jens Kuhle in Multiple Sclerosis Journal</p

    sj-docx-2-msj-10.1177_13524585211047977 – Supplemental material for Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis

    No full text
    Supplemental material, sj-docx-2-msj-10.1177_13524585211047977 for Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis by Tomas Uher, Eva Kubala Havrdova, Pascal Benkert, Niels Bergsland, Jan Krasensky, Barbora Srpova, Michael Dwyer, Michaela Tyblova, Stephanie Meier, Manuela Vaneckova, Dana Horakova, Robert Zivadinov, David Leppert, Tomas Kalincik and Jens Kuhle in Multiple Sclerosis Journal</p

    sj-docx-1-msj-10.1177_13524585211032348 – Supplemental material for Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS

    No full text
    Supplemental material, sj-docx-1-msj-10.1177_13524585211032348 for Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS by Jens Kuhle, Nadia Daizadeh, Pascal Benkert, Aleksandra Maceski, Christian Barro, Zuzanna Michalak, Maria Pia Sormani, Jean Godin, Srinivas Shankara, Tarek A Samad, Alan Jacobs, Luke Chung, Nora Rӧsch, Carina Kaiser, Colin P Mitchell, David Leppert, Evis Havari and Ludwig Kappos in Multiple Sclerosis Journal</p

    sj-docx-1-msj-10.1177_13524585231198760 – Supplemental material for Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis

    No full text
    Supplemental material, sj-docx-1-msj-10.1177_13524585231198760 for Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis by Nuria Cerdá-Fuertes, Marc Stoessel, Gintaras Mickeliunas, Silvan Pless, Alessandro Cagol, Muhamed Barakovic, Aleksandra Maleska Maceski, Cesar Álvarez González, Marcus D’ Souza, Sabine Schaedlin, Pascal Benkert, Pasquale Calabrese, Konstantin Gugleta, Tobias Derfuss, Till Sprenger, Cristina Granziera, Yvonne Naegelin, Ludwig Kappos, Jens Kuhle and Athina Papadopoulou in Multiple Sclerosis Journal</p

    sj-docx-2-msj-10.1177_13524585231198760 – Supplemental material for Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis

    No full text
    Supplemental material, sj-docx-2-msj-10.1177_13524585231198760 for Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis by Nuria Cerdá-Fuertes, Marc Stoessel, Gintaras Mickeliunas, Silvan Pless, Alessandro Cagol, Muhamed Barakovic, Aleksandra Maleska Maceski, Cesar Álvarez González, Marcus D’ Souza, Sabine Schaedlin, Pascal Benkert, Pasquale Calabrese, Konstantin Gugleta, Tobias Derfuss, Till Sprenger, Cristina Granziera, Yvonne Naegelin, Ludwig Kappos, Jens Kuhle and Athina Papadopoulou in Multiple Sclerosis Journal</p

    sj-docx-1-msj-10.1177_13524585241234783 – Supplemental material for Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study

    No full text
    Supplemental material, sj-docx-1-msj-10.1177_13524585241234783 for Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study by Xavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, Pascal Benkert, Douglas L Arnold, Martin S Weber, Andrea Seitzinger, Hans Guehring, Jamie Shaw, Davorka Tomic, Yann Hyvert, Danielle E Harlow, Martin Dyroff and Jerry S Wolinsky in Multiple Sclerosis Journal</p
    corecore